StockUS listing USGUTSNASDAQHealthcareEarnings Deterioration

Fractyl Health, Inc. Common Stock(GUTS) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk72High
75%Data
Revenue down 57% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 10.88M
Reward Ratingⓘ40 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ72 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GUTS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Fractyl Health, Inc. Common Stock?

, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.

AI Brief Pro

The brief on Fractyl Health, Inc. Common Stock

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Fractyl Health, Inc. Common Stock?

, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 10.88M.

Financial Highlights

Investment Breakdown

Growth
Growth trend is developing — watch for revenue consistency over upcoming quarters.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.888
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
164,516 shares
$40k
3-6months
0
5171,493 shares
$127k
6-9months
0
0
9-12months
0
110,416 shares
$20k